Insight Pharma Report announces it's newest report with expanded focus, coverage and primary data!

NEEDHAM, MASSACHUSETTS, UNITED STATES, October 23, 2013 /EINPresswire.com/ -- Cambridge Healthtech Institute’s Insight Pharma Reports announces Macrocycles: Discovery, Development & Technologies. This report covers background material including a more in depth analysis of what macrocycles are and the pharmacokinetic properties (absorption, distribution, metabolism, and excretion) they exhibit. Challenges, benefits, and additional properties that are considered with their development as drugs are covered as well. Additionally, this report details specifics in technologies and current research in development.

This newly published report includes:
-Expert Interviews
-Primary data including survey results
-In depth analysis of what macrocycles are and the pharmacokinetic properties they exhibit
-Reviews specifics in technologies and current research in development
-Detailed descriptions of company overviews, technology platforms, benefits, challenges, competitive advantages, partnerships and future aspirations

Macrocycles are a drug class consisting of small to medium sized natural, semi-natural, or artificial molecules where atoms are connected in such a way that they form a ring, providing rigidity and stability to the structure. Traditionally, macrocycles are cyclic compounds or peptides that vary in size, and are typically 500-2,000 Da. With such a variety in size, the bigger the molecule the more flexibility in structural combinations, allowing scientists to fine-tune the molecules’ function and performance. Macrocycles are unique compounds in that larger molecules still maintain structural organization and stability, whereas linear molecules can usually adopt several different combinations; providing the necessary structural foundation for scientists to work with and apply to various areas of drug development, creating a footprint for a wide line of therapeutics.

Chapters 3-12 detail various companies and their strategies for studying macrocycles as drug candidates and Insight Pharma Reports has received the participation of:

-Aileron Therapeutics
-Bicycle Therapeutics
-Encycle Therapeutics
-Ensemble Therapeutics
-Lanthio Pharma
-Oncodesign
-Pepscan
-PeptiDream
-RA Pharmaceuticals
-Tranzyme Pharmaceuticals

Specific highlights covered in each section include detailed descriptions of company overviews, technology platforms, benefits, challenges, competitive advantages, partnerships and future aspirations. Also provided are exclusive interviews at the end of each section.

Also exclusive to this report is a survey conducted by Insight Pharma Reports. This survey includes over 90 participants from the various organizations including academic and government institutions, pharmaceutical companies, and biotechnology companies. These results are mentioned and analyzed at the end of the report.

For more information and to purchase this Insight Pharma Report, visit: www.InsightPharmaReports.com

About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. www.InsightPharmaReports.com

Kerri Simpson
Insight Pharma Reports
7819721347
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.